84.56

3.54% -3.515

Glaukos Corporation (GKOS)

Overview News Price History Option Chain Financials Discussions Forecast

Glaukos Corporation stock is traded at $84.56, with a volume of 205.89K. It is down -3.54% in the last 24 hours and down -2.81% over the past month. Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Previous Close:

$88.07

Open:

$88.09

24h Volume:

205.89K

Relative Volume:

0.20

Market Cap:

$4.85B

Revenue:

$360.35M

Net Income/Loss:

$-149.57M

P/E Ratio:

-28.57

EPS:

-2.96

Net Cash Flow:

$-81.27M

1W Performance:

+12.26%

1M Performance:

-2.81%

6M Performance:

-3.03%

1Y Performance:

-35.53%

1-Day Range:

$84.34

$88.67

1-Week Range:

$73.16

$102.80

52-Week Range:

$73.16

$163.71

Glaukos Corporation Stock (GKOS) Company Profile

Name

Glaukos Corporation

Sector

Healthcare (1137)

Industry

Medical Devices (144)

Phone

949-367-9600

Address

1 GLAUKOS WAY, ALISO VIEJO, CA

Employee

995

Twitter

@GlaukosCorp

Next Earnings Date

2024-11-04

Latest SEC Filings

GKOS's Discussions on Twitter

Compare GKOS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GKOS Glaukos Corporation	84.56	5.06B	360.35M	-149.57M	-81.27M	-2.96
ABT Abbott Laboratories	122.78	214.96B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	98.63	149.24B	19.35B	2.78B	3.49B	1.8696
SYK Stryker Corp	357.15	136.23B	24.38B	2.94B	4.02B	7.6145
MDT Medtronic Plc	89.22	116.33B	34.20B	4.69B	5.30B	3.6218
EW Edwards Lifesciences Corp	80.85	48.41B	5.88B	1.34B	577.90M	2.3455

Glaukos Corporation Stock (GKOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-01-25	Initiated	Goldman	Buy
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-06-24	Initiated	UBS	Buy
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-24	Downgrade	Citigroup	Buy → Neutral
May-06-24	Upgrade	Jefferies	Hold → Buy
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight
Nov-28-23	Initiated	Truist	Buy
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-22-22	Initiated	Mizuho	Neutral
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight
Oct-04-22	Initiated	Needham	Buy
Jul-12-22	Upgrade	Stifel	Hold → Buy
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight
Jul-14-21	Downgrade	Oppenheimer	Outperform → Perform
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Apr-08-21	Upgrade	Oppenheimer	Perform → Outperform
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Upgrade	Citigroup	Sell → Neutral
Dec-09-20	Initiated	Oppenheimer	Perform
Nov-17-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Oct-08-20	Downgrade	JP Morgan	Neutral → Underweight
Jun-15-20	Initiated	Jefferies	Hold
Mar-05-20	Initiated	Citigroup	Sell
Feb-28-20	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-20	Upgrade	Berenberg	Hold → Buy
Dec-12-19	Downgrade	Wells Fargo	Outperform → Underperform
Sep-30-19	Downgrade	BofA/Merrill	Buy → Underperform
Mar-08-19	Initiated	BTIG Research	Neutral
Aug-30-18	Initiated	Berenberg	Hold
Aug-29-18	Upgrade	JP Morgan	Neutral → Overweight
Aug-03-18	Reiterated	Stifel	Hold
Jun-21-18	Downgrade	JP Morgan	Overweight → Neutral
Apr-13-18	Downgrade	Stifel	Buy → Hold
Mar-01-18	Reiterated	Cantor Fitzgerald	Buy
Mar-02-17	Reiterated	Cantor Fitzgerald	Overweight
Jan-06-17	Upgrade	Stifel	Hold → Buy
Oct-27-16	Initiated	Wells Fargo	Outperform

View All

Glaukos Corporation Stock (GKOS) Latest News

08:01 AM

Why Glaukos Corporation stock appears on watchlists2025 Price Momentum & High Accuracy Swing Trade Signals - newser.com

08:01 AM

07:00 AM

Glaukos Announces Participation in Upcoming Investor Conferences - The AI Journal

07:00 AM

Glaukos (NYSE: GKOS) to join five investor conferences; Nov–Dec 2025 webcasts - Stock Titan

07:00 AM

06:38 AM

Zweig DiMenna Associates LLC Sells 52,200 Shares of Glaukos Corporation $GKOS - MarketBeat

06:38 AM

04:54 AM

Will Glaukos Corporation continue its uptrendMarket Growth Report & Reliable Price Action Trade Plans - newser.com

04:54 AM

04:49 AM

Is Glaukos Corporation stock a bargain at current levelsJuly 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com

04:49 AM

04:39 AM

Can Glaukos Corporation stock expand revenue streams2025 Dividend Review & Safe Capital Investment Plans - newser.com

04:39 AM

03:46 AM

What risks investors should watch in Glaukos Corporation stock2025 Volatility Report & Low Drawdown Trading Techniques - newser.com

03:46 AM

03:22 AM

Is Glaukos Corporation stock attractive for income investors2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com

03:22 AM

02:15 AM

FY2025 Earnings Forecast for Glaukos Issued By William Blair - MarketBeat

02:15 AM

01:58 AM

Backtesting results for Glaukos Corporation trading strategiesWatch List & Daily Entry Point Trade Alerts - newser.com

01:58 AM

01:20 AM

How Glaukos Corporation stock performs in stagflationJuly 2025 Action & Smart Allocation Stock Tips - newser.com

01:20 AM

Nov 02, 2025

Key metrics from Glaukos Corporation’s quarterly dataGap Up & Free Fast Entry Momentum Trade Alerts - newser.com

Nov 02, 2025

How Glaukos Corporation (6GJ) stock responds to job market shiftsJuly 2025 Sector Moves & Growth Focused Stock Reports - newser.com

Nov 02, 2025

Glaukos (GKOS) Is Up 17.9% After FDA Approval of Epioxa and Record Q3 Results Has the Bull Case Changed? - simplywall.st

Nov 02, 2025

Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth - MSN

Nov 02, 2025

Can Glaukos Corporation (6GJ) stock sustain free cash flow2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com

Nov 02, 2025

Is Glaukos Corporation stock dividend yield sustainableMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - newser.com

Nov 02, 2025

Is Glaukos Corporation stock cheap by valuation metricsTrend Reversal & Stepwise Trade Execution Plans - newser.com

Nov 02, 2025